Skip to content

Opioid-free Total Hip Arthroplasty

Opioid-free Total Hip Arthroplasty: A Randomized Controlled Trial

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04421196
Enrollment
0
Registered
2020-06-09
Start date
2022-09-15
Completion date
2023-12-01
Last updated
2022-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Osteoarthritis

Brief summary

The primary objective of investigators' proposed study is to demonstrate that the following two cohorts undergoing total hip arthroplasty will have equivalent visual analog scale (VAS) scores up to 3 months post-operatively: one that is administered a modified multimodal analgesic pathway without opioids and the other administered the current standard multimodal analgesic pathway used at Johns Hopkins Bayview Hospital (which includes opioids). The secondary objective is to demonstrate that these cohorts will also have equivalent functional outcomes as determined by both objective measures (such as hip range of motion) and patient-reported outcome measures, such as the Hip Disability and Osteoarthritis Outcome Score (HOOS) and the University of California at Los Angeles (UCLA) activity score.

Interventions

OTHERExclusion of opioid analgesics

The intervention involves removing the option of patients having an opioid analgesic at any time point during the perioperative period.

Sponsors

Johns Hopkins University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Randomized controlled trial

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients of all ages with end-stage primary hip osteoarthritis.

Exclusion criteria

* Patients with creatinine clearance between 30 and 60 mL/min * Use of any opioid analgesics in the 6 months preceding surgery * Revision total hip arthroplasty * Patients with liver insufficiency * Patients on chronic anticoagulation * Workers compensation patients * Patients who cannot receive Acetaminophen, Ketorolac, Celecoxib, or Gabapentin for any reason (e.g. allergies)

Design outcomes

Primary

MeasureTime frameDescription
Change in post-operative pain assessed by the Visual analog scale (VAS) pain scoresFrom immediate post-operative period to 3 months post-operativelyPost-operative pain scores ranging from 0 to 10; 0 being no pain and 10 being the worst pain ever felt

Secondary

MeasureTime frameDescription
Change in pain satisfaction as assessed by Hip Disability and Osteoarthritis Outcome Score (HOOS)From pre-operative clinic visit to immediate post-operative period, then to 3 months post-operativelyA patient-reported measure that assesses components such as assesses patient pain, satisfaction including stiffness and range of motion, activity limitations-daily living, sports and recreation function, and quality of life. Scores range from 0 to 100 with a score of 0 indicating the worst possible hip symptoms and 100 indicating no hip symptoms.
Change in Physical Activity level as assessed by the University of California at Los Angeles (UCLA) ScaleFrom pre-operative clinic visit to immediate post-operative period, and then to 3 months post-operativelyThe UCLA scale is a patient-reported measure ranging from 1 to 10. Patients indicate their most appropriate activity level, with 1 defined as no physical activity, dependent on others and 10 defined as regular participation in impact sports.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026